Your browser doesn't support javascript.
loading
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis, Gwenaëlle; Billon, Emilien; Baldini, Capucine; Massard, Christophe; Hilgers, Werner; Delva, Remy; Walz, Jochen; Pignot, Geraldine; Rybikowski, Stanislas; Dermeche, Slimane; Thomassin, Jeanne; Brunelle, Serge; Lavaud, Pernelle; Loriot, Yohann.
Afiliação
  • Gravis G; From the Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France; Medical Oncology, Institut Paoli-Calmettes, Marseille, France. Electronic address: gravisg@ipc.unicancer.fr.
  • Billon E; Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Baldini C; Drug Development Department (DITEP), Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Massard C; Drug Development Department (DITEP), Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Hilgers W; Medical Oncology, Institut Sainte Catherine, Avignon, France.
  • Delva R; Medical Oncology, Centre Paul Papin, Angers, France.
  • Walz J; Surgical Urology, Institut Paoli-Calmettes, Marseille, France.
  • Pignot G; Surgical Urology, Institut Paoli-Calmettes, Marseille, France.
  • Rybikowski S; Surgical Urology, Institut Paoli-Calmettes, Marseille, France.
  • Dermeche S; Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Thomassin J; Biopathology Department Institut Paoli-Calmettes, Marseille, France.
  • Brunelle S; Radiology Department Institut Paoli-Calmettes, Marseille, France.
  • Lavaud P; Département de Médecine Oncologique, Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Loriot Y; Département de Médecine Oncologique, Gustave Roussy, University of Paris Sud, Villejuif, France.
Eur J Cancer ; 104: 236-238, 2018 11.
Article em En | MEDLINE | ID: mdl-30316610
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Cisplatino / Terapia de Salvação / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Imunoterapia / Proteínas de Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Cisplatino / Terapia de Salvação / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Imunoterapia / Proteínas de Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article